EGRX
Price:
$0.58
Market Cap:
$7.52M
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blo...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2014-02-12
Stock Exchange
NASDAQ
Ticker
EGRX
According to Eagle Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is 17.39%. This represents a change of 983.20% compared to the average of 1.61% of the last 4 quarters.
The mean historical ROE of Eagle Pharmaceuticals, Inc. over the last ten years is 7.60%. The current 17.39% ROE has changed 128.66% with respect to the historical average. Over the past ten years (40 quarters), EGRX's ROE was at its highest in in the December 2016 quarter at 37.89%. The ROE was at its lowest in in the December 2013 quarter at -420.17%.
Average
7.60%
Median
7.22%
Minimum
-54.32%
Maximum
53.86%
Discovering the peaks and valleys of Eagle Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.79%
Maximum Annual ROE = 53.86%
Minimum Annual Increase = -412.13%
Minimum Annual ROE = -54.32%
Year | ROE | Change |
---|---|---|
2023 | 0% | -100.00% |
2022 | 15.26% | -412.13% |
2021 | -4.89% | -175.86% |
2020 | 6.45% | -19.32% |
2019 | 7.99% | -59.75% |
2018 | 19.84% | -31.56% |
2017 | 29.00% | -46.17% |
2016 | 53.86% | 1.79% |
2015 | 2.85% | -105.24% |
2014 | -54.32% | -81.55% |
The current ROE of Eagle Pharmaceuticals, Inc. (EGRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
3.46%
5-year avg
4.96%
10-year avg
7.60%
Eagle Pharmaceuticals, Inc.’s ROE is greater than ANI Pharmaceuticals, Inc. (-1.60%), less than Phibro Animal Health Corporation (6.59%), greater than Deciphera Pharmaceuticals, Inc. (-52.42%), less than Prestige Consumer Healthcare Inc. (12.35%), less than Collegium Pharmaceutical, Inc. (40.81%), greater than Silver Spike Investment Corp. (0%), greater than Regencell Bioscience Holdings Limited (-48.12%), less than Amphastar Pharmaceuticals, Inc. (22.92%), less than Alkermes plc (26.49%), greater than Evolus, Inc. (-966.29%), less than Procaps Group, S.A. (97.17%), less than Delta 9 Cannabis Inc. (484.43%), greater than RAMM Pharma Corp. (-32.53%), less than City View Green Holdings Inc. (51.86%), greater than Craftport Cannabis Corp. (-194.22%), greater than Speakeasy Cannabis Club Ltd. (-16.76%),
Company | ROE | Market cap |
---|---|---|
-1.60% | $1.14B | |
6.59% | $876.50M | |
-52.42% | $2.21B | |
12.35% | $3.88B | |
40.81% | $940.09M | |
0% | $66.72M | |
-48.12% | $62.07M | |
22.92% | $1.88B | |
26.49% | $4.77B | |
-966.29% | $686.41M | |
97.17% | $283.19M | |
484.43% | $1.38M | |
-32.53% | $15.16M | |
51.86% | $730.24K | |
-194.22% | $6.27B | |
-16.76% | $1.31K |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Eagle Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Eagle Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Eagle Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Eagle Pharmaceuticals, Inc. (EGRX)?
What is the highest ROE for Eagle Pharmaceuticals, Inc. (EGRX)?
What is the 3-year average ROE for Eagle Pharmaceuticals, Inc. (EGRX)?
What is the 5-year average ROE for Eagle Pharmaceuticals, Inc. (EGRX)?
How does the current ROE for Eagle Pharmaceuticals, Inc. (EGRX) compare to its historical average?